INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 55 filers reported holding INOZYME PHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,639,057 | -15.5% | 628,347 | +12.0% | 0.00% | – |
| Q2 2023 | $3,123,890 | +456.0% | 560,842 | +472.0% | 0.00% | – |
| Q1 2023 | $561,855 | +250.4% | 98,055 | -35.8% | 0.00% | – |
| Q4 2022 | $160,346 | -21.8% | 152,710 | +100.0% | 0.00% | – |
| Q3 2022 | $205,000 | -12.4% | 76,355 | +55.7% | 0.00% | – |
| Q2 2022 | $234,000 | -69.7% | 49,055 | -74.0% | 0.00% | – |
| Q1 2022 | $773,000 | -39.4% | 189,005 | +1.0% | 0.00% | – |
| Q4 2021 | $1,276,000 | -41.5% | 187,102 | -0.6% | 0.00% | – |
| Q3 2021 | $2,182,000 | -24.6% | 188,267 | +10.8% | 0.00% | – |
| Q2 2021 | $2,895,000 | +10.6% | 169,889 | +28.5% | 0.00% | – |
| Q1 2021 | $2,618,000 | +7.9% | 132,219 | +12.5% | 0.00% | – |
| Q4 2020 | $2,427,000 | +30.8% | 117,579 | +66.6% | 0.00% | – |
| Q3 2020 | $1,856,000 | – | 70,585 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 1,009,117 | $26,529,000 | 9.44% |
| YALE UNIVERSITY | 113,502 | $2,984,000 | 9.13% |
| Sofinnova Investments, Inc. | 2,028,308 | $53,324,000 | 3.95% |
| Novo Holdings A/S | 2,569,379 | $67,549,000 | 3.35% |
| NEA Management Company, LLC | 2,444,379 | $64,263,000 | 2.72% |
| RA Capital Management | 2,003,653 | $52,676,000 | 0.96% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,150,299 | $30,241,000 | 0.74% |
| Rock Springs Capital Management LP | 879,954 | $23,134,000 | 0.59% |
| SPHERA FUNDS MANAGEMENT LTD. | 196,411 | $5,164,000 | 0.51% |
| Orbimed Advisors | 400,400 | $10,527,000 | 0.13% |